Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 4Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia 2Rectal Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Congenital Abnormalities 1Colorectal Neoplasms 1Colonic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 33Etoposide 16Daunorubicin 16tipifarnib 10Mitoxantrone 10Idarubicin 9Azacitidine 8alvocidib 6Filgrastim 6Busulfan 6Peripheral Blood Stem Cell Transplantation 5valspodar 4Sorafenib 4Bortezomib 4fludarabine phosphate 3entinostat 3aldesleukin 3Vorinostat 3Tretinoin 3Radiotherapy 3Lenalidomide 3Gemtuzumab 3Decitabine 3Cyclophosphamide 3veliparib 2tanespimycin 2sargramostim 2lintuzumab 2laromustine 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myelomonocytic, Acute × Cytogenetic Analysis × Clear all
NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡